KR101778316B1 - 인공 눈물 및 치료학적 용도 - Google Patents

인공 눈물 및 치료학적 용도 Download PDF

Info

Publication number
KR101778316B1
KR101778316B1 KR1020127000233A KR20127000233A KR101778316B1 KR 101778316 B1 KR101778316 B1 KR 101778316B1 KR 1020127000233 A KR1020127000233 A KR 1020127000233A KR 20127000233 A KR20127000233 A KR 20127000233A KR 101778316 B1 KR101778316 B1 KR 101778316B1
Authority
KR
South Korea
Prior art keywords
oil
delete delete
castor oil
mixture
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127000233A
Other languages
English (en)
Korean (ko)
Other versions
KR20120046151A (ko
Inventor
아누라다 브이. 고어
로버트 에스. 조단
케빈 크록
체탄 푸자라
Original Assignee
알러간, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42312750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101778316(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 알러간, 인코포레이티드 filed Critical 알러간, 인코포레이티드
Publication of KR20120046151A publication Critical patent/KR20120046151A/ko
Application granted granted Critical
Publication of KR101778316B1 publication Critical patent/KR101778316B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
KR1020127000233A 2009-06-05 2010-06-03 인공 눈물 및 치료학적 용도 Expired - Fee Related KR101778316B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18433909P 2009-06-05 2009-06-05
US61/184,339 2009-06-05
PCT/US2010/037153 WO2010141648A2 (en) 2009-06-05 2010-06-03 Artificial tears and therapeutic uses

Publications (2)

Publication Number Publication Date
KR20120046151A KR20120046151A (ko) 2012-05-09
KR101778316B1 true KR101778316B1 (ko) 2017-09-13

Family

ID=42312750

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127000233A Expired - Fee Related KR101778316B1 (ko) 2009-06-05 2010-06-03 인공 눈물 및 치료학적 용도

Country Status (24)

Country Link
US (7) US8496976B2 (enExample)
EP (1) EP2437762B1 (enExample)
KR (1) KR101778316B1 (enExample)
CN (2) CN102458430A (enExample)
AU (1) AU2010256652B2 (enExample)
BR (1) BRPI1011710B8 (enExample)
CA (1) CA2764802A1 (enExample)
DK (1) DK2437762T3 (enExample)
ES (1) ES2646338T3 (enExample)
HK (1) HK1214943A1 (enExample)
HR (1) HRP20171691T1 (enExample)
HU (1) HUE034213T2 (enExample)
IL (1) IL216800A (enExample)
LT (1) LT2437762T (enExample)
MX (2) MX2011013007A (enExample)
MY (1) MY172185A (enExample)
NO (1) NO2437762T3 (enExample)
NZ (1) NZ596932A (enExample)
PL (1) PL2437762T3 (enExample)
PT (1) PT2437762T (enExample)
RU (1) RU2589837C2 (enExample)
SI (1) SI2437762T1 (enExample)
WO (1) WO2010141648A2 (enExample)
ZA (1) ZA201108979B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210009947A (ko) 2019-07-18 2021-01-27 윤영선 산소가 도입된 점안제, 및 그 제조방법

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
NO2437762T3 (enExample) 2009-06-05 2018-01-06
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
PL2787968T3 (pl) * 2011-12-07 2020-08-24 Allergan, Inc. Wydajne dostarczanie lipidów do ludzkiego filmu łzowego z użyciem wrażliwego na sól układu emulsyjnego
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US9278132B2 (en) * 2012-02-13 2016-03-08 Bausch & Lomb Incorporated Ophthalmic pharmaceutical compositions and methods of making and using same
US10085960B2 (en) 2012-03-30 2018-10-02 Brien Holden Vision Institute Methods and compositions for reducing ocular discomfort
US9289494B2 (en) 2013-11-20 2016-03-22 RestorTears, LLC Method of treating ocular disorders with compounds found in Harderian gland secretions
SG11201704010UA (en) 2014-08-20 2017-06-29 Silk Tech Ltd Fibroin-derived protein composition
KR102487299B1 (ko) * 2014-11-25 2023-01-10 알러간, 인코포레이티드 안정화된 오메가-3 안과용 조성물
EP3362096B1 (en) 2015-10-14 2023-12-13 Paul Gavaris Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents
SG11201808804TA (en) 2016-04-08 2018-11-29 Univ Cornell A method to enhance wound healing using silk-derived protein
US11478437B2 (en) 2016-07-05 2022-10-25 Jenivision Inc. Formulations for hair growth
DK3266446T3 (en) 2016-07-07 2019-02-11 Salvat Lab Sa Eye preparation comprising castor oil and medium chain triglyceride
CA3033507A1 (en) 2016-08-12 2018-02-15 Silk Technologies, Ltd. Silk-derived protein for treating inflammation
CA3032695C (en) * 2016-08-19 2021-11-23 Akrivista, LLC Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
GB201618175D0 (en) * 2016-10-27 2016-12-14 Warneford Healthcare Ltd Pharmaceutical compositions
CN110996964A (zh) * 2017-06-30 2020-04-10 杰尼视界公司 用于毛发生长的制剂
BR112020003276A2 (pt) 2017-08-18 2020-09-01 Akrivista, LLC métodos de diagnóstico e tratamento da síndrome do olho seco e composições para tratamento de um olho humano
US20200030226A1 (en) 2018-07-27 2020-01-30 Johnson & Johnson Consumer Inc. Botanical and bacterial extracts displaying retinol-like activity
CN115671090A (zh) 2018-07-27 2023-02-03 强生外科视力公司 用于治疗眼睛的组合物和方法
US11197841B2 (en) 2019-07-23 2021-12-14 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
CA3106898A1 (en) 2018-07-27 2020-01-30 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
WO2020021481A1 (en) 2018-07-27 2020-01-30 Johnson & Johnson Vision Care, Inc. Compositions and methods for treating the eye
US10966948B2 (en) 2019-07-23 2021-04-06 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
BR112021000724A2 (pt) 2018-07-27 2021-04-13 Johnson & Johnson Surgical Vision, Inc. Composições e métodos para tratar os olhos
US11166997B2 (en) 2018-07-27 2021-11-09 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
US11045416B2 (en) 2018-08-30 2021-06-29 Johnson & Johnson Consumer Inc. Topical compositions comprising Pichia anomala and retinol
US11110051B2 (en) 2018-08-30 2021-09-07 Johnson & Johnson Consumer Inc. Topical compositions comprising Pichia anomala and n-acetyl glucosamine
EP3824895A1 (en) 2019-11-19 2021-05-26 Johnson & Johnson Consumer Inc. Compositions and methods for treating the eye
US11969454B2 (en) 2019-11-19 2024-04-30 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
US11969451B2 (en) 2019-11-19 2024-04-30 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
EP3824877A1 (en) 2019-11-19 2021-05-26 Johnson & Johnson Consumer Inc. Compositions and methods for treating the eye
EP4059508A1 (en) 2021-03-19 2022-09-21 Johnson & Johnson Consumer Inc. Methods of using compositions comprising an iceland moss extract

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060251685A1 (en) * 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
US20070015694A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
WO2008106228A2 (en) * 2007-02-28 2008-09-04 Aciex Therapeutics, Inc. Methods and compositions for normalizing meibomian gland secretions

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56104814A (en) * 1980-01-25 1981-08-20 Kunihiro Okanoe Preparation of eye drop
US4649047A (en) 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
WO1989001772A1 (en) 1987-09-03 1989-03-09 University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
CH679210A5 (enExample) * 1988-10-26 1992-01-15 Sandoz Ag
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
AU1172097A (en) 1995-12-27 1997-07-28 Rohto Pharmaceutical Co., Ltd. Pharmaceutical composition containing trehalose
US5981607A (en) * 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
GB0012597D0 (en) 2000-05-25 2000-07-12 Astrazeneca Ab Formulation
US7027446B2 (en) 2001-07-18 2006-04-11 P-Cube Ltd. Method and apparatus for set intersection rule matching
JP4284491B2 (ja) 2002-07-16 2009-06-24 豊和工業株式会社 ピストン外形の加工データ生成装置
TWI335819B (en) * 2002-12-24 2011-01-11 Alcon Inc Use of oculosurface selective glucocorticoid in the treatment of dry eye
KR20120066688A (ko) * 2003-02-24 2012-06-22 파마슈티칼 프로덕션스, 인크. 경점막 약물 전달 시스템
US20040185068A1 (en) 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
AU2005262392A1 (en) 2004-07-01 2006-01-19 Johnson & Johnson Vision Care, Inc. Compositions and methods for treating eye disorders and conditions
MX2007002400A (es) * 2004-08-27 2007-05-04 Senju Pharma Co Liquido para lavado de ojos para terapia de ojos secos.
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
CN100562340C (zh) * 2005-06-17 2009-11-25 中国科学院上海药物研究所 一种微乳型人工泪液
US7202209B2 (en) 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
WO2008035246A2 (en) 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
WO2008027341A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
CN101554369B (zh) * 2008-05-12 2012-07-25 陈亚玲 一种外用复合油纳米乳喷雾剂和滴眼剂及其制备方法
UA36915U (uk) * 2008-05-28 2008-11-10 Львівський Національний Медичний Університет Ім. Данила Галицького Очні краплі для лікування запальних захворювань судинної оболонки та сухого кератокон'юнктивіту, які викликані аутоімунними процесами
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
US9480645B2 (en) 2009-06-02 2016-11-01 Abbott Medical Optics Inc. Omega-3 oil containing ophthalmic emulsions
NO2437762T3 (enExample) 2009-06-05 2018-01-06

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060251685A1 (en) * 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
US20070015694A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
WO2008106228A2 (en) * 2007-02-28 2008-09-04 Aciex Therapeutics, Inc. Methods and compositions for normalizing meibomian gland secretions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Khanal, Santosh, et al. Cornea, 2007, 26(2), 175-181*

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210009947A (ko) 2019-07-18 2021-01-27 윤영선 산소가 도입된 점안제, 및 그 제조방법
KR20210071921A (ko) 2019-07-18 2021-06-16 윤영선 산소가 도입된 점안제, 및 그 제조방법

Also Published As

Publication number Publication date
ZA201108979B (en) 2012-08-29
IL216800A (en) 2017-03-30
US8679554B2 (en) 2014-03-25
WO2010141648A3 (en) 2011-03-10
KR20120046151A (ko) 2012-05-09
NZ596932A (en) 2014-04-30
US20140141106A1 (en) 2014-05-22
US9821020B2 (en) 2017-11-21
BRPI1011710A8 (pt) 2019-11-05
CA2764802A1 (en) 2010-12-09
BRPI1011710B8 (pt) 2021-05-25
US20250082709A1 (en) 2025-03-13
US20180264063A1 (en) 2018-09-20
CN102458430A (zh) 2012-05-16
MY172185A (en) 2019-11-15
HUE034213T2 (en) 2018-01-29
HK1214943A1 (zh) 2016-08-12
BRPI1011710B1 (pt) 2021-01-26
PT2437762T (pt) 2017-11-14
US20120201910A1 (en) 2012-08-09
ES2646338T3 (es) 2017-12-13
US20240108677A1 (en) 2024-04-04
US20220008496A1 (en) 2022-01-13
HRP20171691T1 (hr) 2017-12-15
BRPI1011710A2 (pt) 2016-03-22
SI2437762T1 (en) 2018-02-28
US20130295206A1 (en) 2013-11-07
LT2437762T (lt) 2017-11-27
CN104906170A (zh) 2015-09-16
EP2437762B1 (en) 2017-08-09
AU2010256652B2 (en) 2015-11-26
RU2011151468A (ru) 2013-07-20
US11045515B2 (en) 2021-06-29
MX358504B (es) 2018-08-21
US8496976B2 (en) 2013-07-30
WO2010141648A2 (en) 2010-12-09
EP2437762A2 (en) 2012-04-11
NO2437762T3 (enExample) 2018-01-06
IL216800A0 (en) 2012-02-29
DK2437762T3 (da) 2017-11-20
RU2589837C2 (ru) 2016-07-10
AU2010256652A1 (en) 2012-01-12
PL2437762T3 (pl) 2018-01-31
MX2011013007A (es) 2012-02-28

Similar Documents

Publication Publication Date Title
US20250082709A1 (en) Artificial tears and therapeutic uses
DE3851152T2 (de) Cyclosporin-augenmittel.
KR102017922B1 (ko) 염-민감성 유액 시스템을 사용한 사람 눈물막으로의 효율적인 지질 전달 방법
Mustafoyeva et al. FULL FACTS ABOUT DRY EYE
HK1169046A (en) Artificial tears and therapeutic uses
DE202017103487U1 (de) Osmolyt in Kombination mit lipophiler Grundlage
CN101780076A (zh) 一种含有他克莫司的药物组合物用于干眼症治疗的用途
Goldstein et al. Dry Eye Disease
RU2772357C2 (ru) Состав для эффективной доставки липидов в слезную пленку человека с использованием чувствительной к соли эмульсионной системы
Achyut Management of severe dry eye: role of autologous serum eye drops
HK1203057B (en) Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
NZ743307A (en) Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
NZ743307B2 (en) Efficient lipid delivery to human tear film using a salt-sensitive emulsion system

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240908

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240908